PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage biopharmaceutical company focused on the development of regenerative cell therapy for chronic kidney disease, specifically its lead program REACT (Renal Autologous Cell Therapy). The company became publicly traded in January 2023 through a de-SPAC merger with Social Capital Suvretta Holdings Corp. IV, a blank-check vehicle sponsored by Social Capital Suvretta Capital Management. The company filed its most recent Form 10-Q with the SEC on August 10, 2026 (accession no. 0001193125-26-342373), reflecting its continued status as an operating public company in the clinical-stage biotechnology sector. Visit SpacDesk and sign up for full data, filings, and analytics on PROK and hundreds of other SPAC-origin companies.